|
|
|
|
|
|
by a_bonobo
21 hours ago
|
|
|
Yes, getting the drug into the right cell or tissue is still largely unsolved (kidney is easier than brain, of course). But the investors we talk with have dropped all interest in gene editing, too risky. RNA-based technologies are great, though - ASOs, siRNAs etc. Investors are very happy with those :) |
|
|